The automotive sector is undergoing a period of rapid and disruptive transformation from both a business and technical standpoint.
Features
01 March 2004
Doctors depend on pathology labs for accurate diagnoses, and path labs depend on ever more sophisticated LIMS, Peter Rees reports
01 January 2004
More than bioinformatics, systems biology is the coming thing, even if at first it confused Michael Kenward
01 January 2004
Robust control theory has some surprising applications, and software can ease the process, writes Brian Cogan
01 January 2004
John Murphy profiles Rama Chellappa, pioneer of image processing and computer vision
01 November 2003
In this final review of 2003, Phillip Hill looks at the collaborations and concentrations that have taken place in the LIMS market this year
01 November 2003
J. Kelly Ganjei, Terry Smallmon and Charles Lee of LabVantage report how LIMS helped a food firm
01 November 2003
ChemBrain doesn't look unusual. It has a straightforward Windows interface and dialogue boxes, albeit in an older style and perhaps slightly inelegant in places. But, aesthetics aside, ChemBrain is different, reports David Bradley
01 November 2003
People differ in many ways, which is why biometrics is a booming business and why Michael Kenward found a wealth of related websites
01 September 2003
John P. Helfrich, from NuGenesis Technologies, believes that a new class of IT product can capture and manage scientific data to improve drug discovery
01 September 2003
Annabel Sedgwick describes how Applied Biosystems is putting researchers firmly in the driving seat in managing their scientific projects
01 September 2003
John Murphy profiles the computational chemistry pioneer and baseball fanatic
01 September 2003
Complex systems are a growing area of research, and finding good sites can be complicated, says Michael Kenward
Pages
Latest issue
Estimates suggest that the global laboratory informatics market, valued at $2.6 billion in 2019, will witness CAGR of 7.5 per cent over the next five years, reaching $3.8 billion in 2024[1].
Modern drug discovery and development workflows incorporate a growing range of automated, high-throughput technologies that can generate data on a truly impressive scale.
‘This will be the life sciences century … because of personalised medicine, information technology, and knowledge on biological systems,’ said Fred Hassan, a partner of Warburg Pincus and former CEO of Schering-Plough.
With data rates increasing and more complex challenges arising in life sciences, Panasas’ Jim Donovan and Dale Brantly discuss the benefits of using HPC for these workloads
As the complexity of both HPC hardware and the challenges that scientists are trying to solve using HPC systems increases, ensuring a system is utilised efficiently is necessary to deliver a computing service with value for money and a high research output.
Architectural specialisation is one option to continue to improve performance beyond the limits imposed by the slow down in Moore’s Law.
As not only the HPC industry but the larger computing ecosystem tries to overcome the slowdown and eventual end of transistor scaling described by Moore’s Law, scientists and researchers are implementing programmes that will define the technologies and new materials needed to supplement, or repla
